Skip to content
Recall Observatory FDA recall evidence

Drug product

Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

D-0583-2026

June 04, 2026

Class II

Product summary

Firm
Breckenridge Pharmaceutical, Inc.
Event
Event 99108
Status
Ongoing
Classification
Class II
Quantity
359,676 bottles
Official record key
drug-enforcement:D-0583-2026

Official wording

Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Code information: Lot: a) 241074C, Exp. Date May 2027; 240317, 240318, 240315C, 240373C, 240370C, 240375C, 240413C, Exp. Date February 2027; 240316,Exp. Date January 2027; 232311, Exp. Date November 2026; b) 240978C, 241052C, Exp. Date April 2027.

Distribution pattern: Nationwide within the United States

Derived failure modes

  • Foreign material or chemical contamination

    reason.foreign_material_chemical_contamination · v1.0.0

    N-nitroso-duloxetine impurity
  • Manufacturing or process control

    reason.manufacturing_process_control · v1.0.0

    CGMP Deviations